Bio-Thera Collaborates with Biomm to Commercialize BAT1706 (biosimilar- bevacizumab) in Brazil
Shots:
- Biomm to get exclusive rights to distribute & market the therapy in Brazil. Bio-Thera will be responsible for development & commercial supply of BAT1706 out of its manufacturing facilities in Guangzhou- China
- Bio-Thera’s BAT1706 has completed a global P-III comparative clinical study assessing the efficacy- safety- PK and immunogenicity of BAT1706 vs EU-bevacizumab + CT in patients with advanced nsq. NSCLC
- Biomm will be responsible for filing the dossier in Brazil. The partnership will leverage Biomm’s presence- sales and marketing capabilities in Brazil
Ref: BusinessWire | Image: Businesswire
Click here to read the full press release
This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com
